Spironolactone for Paroxysmal Atrial Fibrillation

Not Applicable

• Conditions: Atrial Fibrillation
• Interventions: Drug: Spironolactone; Drug: Placebo

• Registration Number: NCT00689598
• Lead Sponsor: Taichung Veterans General Hospital

Brief Summary

To determine whether or not spironolactone can prevent or delay the occurrence of atrial fibrillation.

Detailed Description

To determine whether or not adding spironolactone can prevent or delay the occurrence of paroxysmal atrial fibrillation in patients who have received propafenone treatment.

Study Timeline

• Study Start: 2008-03
• Study First Submitted: 2008-03-30
• Status Verified: 2008-06
• Study First Submitted QC: 2008-06-02
• Study First Posted: 2008-06-03
• Last Update Submitted: 2008-06-04
• Last Update Posted: 2008-06-05
• Primary Completion: 2011-03
• Study Completion: 2011-03

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Experimental	Placebo	Drug intervention
III	Spironolactone	Placebo
Experimental	Spironolactone	Drug intervention

Primary Outcome Measures

Name	Time	Method
time to a first electrocardiographically confirmed AF	3 months

Secondary Outcome Measures

Name	Time	Method
1. Response rate: Improvement of any symptom scores and/or SF36 scores more than 50 % (compared with re-randomization scores) 2. Difference of mean episodes of documented AF between the spironolactone and placebo groups.	3 months

Trial Locations

Locations (1)

Taichung General Hospital; 🇨🇳 Taichung, Taiwan